ASBP News

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement